bioAffinity shares surge 15.38% intraday as new clinical study highlights CyPath Lung's diagnostic value and 2025 sales grow 87.

bioAffinity Technologies surged 15.38% intraday, driven by the release of a new clinical case study demonstrating the CyPath Lung test’s ability to help high-risk patients avoid invasive procedures, record 87% sales and 99% test volume growth in 2025, and a new collaboration with Brooke Army Medical Center to validate the test for early lung cancer detection in tracheal aspirate samples.